Loading...
•
Jun 30, 2022
Madrigal Q2 2022 Earnings Report
Madrigal's financial position improved with the term loan agreement, advancing Phase 3 MAESTRO program and expanding market development activities.
Key Takeaways
Madrigal Pharmaceuticals reported its second quarter 2022 financial results, highlighting the advancement of its Phase 3 MAESTRO program and expansion of market development activities. The company had cash, cash equivalents, and marketable securities of $211.8 million as of June 30, 2022. Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter.
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter.
The MAESTRO-NAFLD-1 results reinforce understanding of the favorable safety and tolerability profile of resmetirom.
Madrigal launched the ‘NASH Explored’ disease education campaign for healthcare providers and announced expanded partnerships with key patient advocacy groups.
Market Access and Medical Affairs teams have conducted NASH disease education sessions with payers that together account for more than 80% of all branded prescriptions in the U.S.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...